Pepper Bio
@pepper_bio
Followers
147
Following
29
Media
26
Statuses
157
The End of Untreatable.
Cambridge, MA
Joined October 2021
"This emphasis on transomics is the future.” Check out CEO @JonYuHu’s recent interview with @GenomeWeb to learn how Pepper Bio is leveraging transomics to better understand biological processes and develop precision medicine. #DrugDiscovery #Transomics
https://t.co/643rWOcsxT
4
2
15
We’ve reached a milestone in our mission to discover new treatments for untreatable diseases. We’re licensing lerociclib from @G1Therapeutics to test it as a new liver cancer therapeutic—and we’re already seeing promising results. More via @FierceBiotech:
fiercebiotech.com
With $6.5 million in seed funding, Pepper Bio has decided to shake up its portfolio
1
0
4
Pepper Bio’s Caitlin Brown will be taking part in #REpharmaUSA 🚀 She’ll be looking to dive into AI in drug discovery & precision medicine discussions. Attending? Let's connect!
0
0
0
#AI in #biotech: not a cure-all, but a powerful tool when combined with human expertise, leading to breakthroughs in disease treatment. The synergy between AI and scientists' insights is where real magic lies. Dive deeper via @STAT @caseymross
statnews.com
AI models can help speed up some parts of the drug development process but experts say the technology is a long way from major breakthroughs.
0
0
0
Exciting developments at @UVACancerCenter! #Machinelearning now identifies high-risk #AML patients by analyzing cancer cell bioactive molecules. Personalized treatment is the future, ensuring safer, more effective care
uvahealth.com
0
0
0
FDA's approval of repotrectinib marks a new chapter in lung cancer therapy, targeting ROS1 fusions with precision. This advancement aligns with our mission—pushing the boundaries of patient-specific treatment and showcasing the power of #precisionmedicine
mskcc.org
Learn more about the new FDA-approved drug repotrectinib (AugtyroTM), which targets ROS1 fusions in lung cancer and other cancer types.
0
0
0
🧬Thank you @HealthTechX for selecting Pepper Bio as a finalist in the Innovator category! We’re dedicated to making ‘untreatable diseases’ a thing of the past. Congrats to our fellow finalists!
0
1
2
Embracing the transformative power of #AI, we're redefining drug discovery at Pepper Bio with efficiency and precision. Mindful of the challenges, we're committed to ethical innovation. Explore AI's future in healthcare in @ClinicalLeader1:
clinicalleader.com
While AI may soon transform the drug discovery and development process, there are still several barriers, both technical and ethical, to the rise of AI in biopharma.
0
0
1
Precision medicine is more than a concept—it's a revolution in healthcare. With a focus on individual biology, we're redefining treatment for complex diseases. Dive into Dr. Jennifer Levin Carter's insights on #precisionmedicine:
benefitnews.com
Tailoring genetic information, environment and lifestyle factors to disease treatment and prevention holds incredible promise.
0
0
1
With a growth rate of 40.2% and revenue expected to hit $4.9B by 2028, AI is reshaping #precisionmedicine, from molecule design to target research. More in @Politico on AI redefining #drugdiscovery:
politico.com
0
0
0
#AI is revolutionizing #clinicaltrials, moving beyond traditional RCTs that slow down therapy development. This isn't just tech evolution, it's a healthcare paradigm shift towards more personalized, efficient treatments. Dive into the full insights:
mckinsey.com
Gen AI is accelerating drug discovery, research, and clinical trials. We look at why clinical development also needs to keep pace with artificial intelligence.
0
0
0
At #JPM2024, our CEO @jonyuhu shared with @PharmaVoice's @MeaganParrish his perspective on what policies will shape biotech in 2024. '"It's not the first time we've heard of march-in rights, but [they] are more mainstream now,' he says. More here:
pharmavoice.com
From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.
0
0
1
Energized by @pepper_bio's feature in @TechCrunch's Pitch Deck Teardown! @Haje's review of our $6.5M seed pitch highlights our mission to treat untreatable diseases. Haje’s praise of our market size slide reflects our areas of commitment
techcrunch.com
This week, we are taking a closer look at Pepper Bio's seed pitch deck that landed the company $6.5 million.
0
3
6
Kicking off 2024 with a feature in @TechCrunch's Pitch Deck Teardown! Thanks to @Haje for the insightful review of our $6.5M seed deck.
techcrunch.com
This week, we are taking a closer look at Pepper Bio's seed pitch deck that landed the company $6.5 million.
1
0
9
We’re welcoming Dr. Martin Alexander Gershon (@endeavorfunds), a renowned neuroscientist, oncologist, and investor, as an advisor to our team! Read more here: https://t.co/RJU5ybRevc
#drugdiscovery #biotech #transomics
biopharmadive.com
0
0
1
See how NFX-backed @pepper_bio and @PangeaBiomed are using AI to help develop better cancer drugs in @WSJ: https://t.co/jrBzHfpkYA
wsj.com
More accurate prognoses and treatments tailored to patients—entrepreneurs claim AI can be harnessed for breakthroughs in beating cancer. One founder is using lab-grown human organs in combination...
0
4
7
“We don’t think the right question is if AI will impact drug discovery, but how and when,” @Jonyuhu said. Jon and @SamanthaDStrass share more on how AI will transform the industry with @BrianPGormley via @WSJ
https://t.co/YW8ZVMIjkR
0
1
1
#AI breakthrough by @UCL & @Cambridge_Uni in #lungcancer risk prediction. This study shows AI's potential to streamline screenings, aiding early detection & treatment. We applaud these advances in healthcare. More here:
1
1
0
Our CEO @Jonyuhu explores how we must redirect the power behind patient advocacy groups to focus on bringing drugs to market that are clinically proven to be effective. Read his proposed solutions in @statnews:
statnews.com
The current state of patient advocacy needs reform so that the best, safest drugs come to market, writes Jon Hu of Pepper Bio.
0
0
1